Somewhat Favorable Media Coverage Somewhat Unlikely to Affect KemPharm (KMPH) Stock Price

News articles about KemPharm (NASDAQ:KMPH) have trended somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm ranks the sentiment of media coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. KemPharm earned a daily sentiment score of 0.07 on Accern’s scale. Accern also assigned media headlines about the specialty pharmaceutical company an impact score of 44.7634837715367 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

KMPH has been the subject of several analyst reports. Zacks Investment Research downgraded KemPharm from a “buy” rating to a “hold” rating in a report on Wednesday. ValuEngine raised KemPharm from a “strong sell” rating to a “sell” rating in a research report on Monday, October 23rd. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and four have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average target price of $8.15.

KemPharm (NASDAQ:KMPH) opened at $5.00 on Friday. The stock has a market capitalization of $73.29, a PE ratio of -1.89 and a beta of -1.09. The company has a debt-to-equity ratio of -1.92, a current ratio of 7.56 and a quick ratio of 7.56. KemPharm has a 12-month low of $2.45 and a 12-month high of $5.40.

In other news, EVP Daniel L. Cohen bought 7,500 shares of the company’s stock in a transaction on Monday, November 27th. The shares were acquired at an average cost of $3.79 per share, with a total value of $28,425.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 22.80% of the company’s stock.

COPYRIGHT VIOLATION WARNING: This report was originally published by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this report on another site, it was illegally copied and republished in violation of international copyright and trademark legislation. The correct version of this report can be read at

About KemPharm

KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).

Insider Buying and Selling by Quarter for KemPharm (NASDAQ:KMPH)

Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with's FREE daily email newsletter.

Leave a Reply